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Abstract 31 
 32 
The selection and design of age-appropriate formulations intended for use in paediatric and 33 
geriatric patients are dependent on multiple factors affecting patient acceptability, safety and 34 
access.  The development of an economic and effective product relies on a balanced 35 
consideration of the risks and benefits of these factors.  This review provides a 36 
comprehensive and up-to-date analysis of oral dosage forms considering key aspects of 37 
formulation design including dosage considerations, ease of use, tolerability and safety, 38 
manufacturing complexity, stability, supply and cost.  Patient acceptability has been 39 
examined utilising an evidence-based approach to evaluate regulatory guidance and 40 
literature.  Safety considerations including excipients and potential risk of administration 41 
errors of the different dosage forms are also discussed, together with possible manufacturing 42 
and supply challenges.  Age appropriate drug product design should consider and compare 43 
i) acceptability ii) safety and iii) access, although it is important to recognise that these 44 
factors must be balanced against each other, and in some situations a compromise may 45 
need to be reached when selecting an age-appropriate formulation. 46 
 47 
Key words Access, Acceptability, Drug product design, Formulation, Geriatric, Manufacture, 48 
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1. Introduction  50 
Patient centric pharmaceutical drug product design may be described as “the process of 51 
identifying the comprehensive needs of individuals or the target patient population and 52 
utilizing the identified needs to design pharmaceutical drug products that provide the best 53 
overall benefit to risk profile for that target population over the intended duration of 54 
treatment” (Stegemann et al., 2016).  The selection and design of patient-centred oral 55 
pharmaceutical dosage forms continues to be one of the most significant challenges in the 56 
development of medicinal products for paediatric and geriatric populations due to the diverse 57 
needs and characteristics of these patient groups. In recent reviews, various patient related 58 
factors have been described (Drumond et al., 2017; Ivanovska et al., 2014; Liu et al., 2014; 59 
van Riet-Nales et al., 2016b; Zajicek et al., 2013)), although most have been in relation to 60 
the development of formulations for use in children.  It is well acknowledged that a broad 61 
range of unique issues need to be taken into consideration in these two heterogeneous 62 
populations, some of which may not be seen to the same extent, if at all, in adults.  For 63 
example, a frequently encountered issue includes determining the suitability of tablet and 64 
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capsules sizes in relation to patients’ age and ability to swallow solid oral dosage forms 65 
(Ranmal and Tuleu, 2013).  Age-related physiological changes and vast differences in 66 
required dose also present particular challenges.  There is still very limited evidence based 67 
data which can be used to provide specific recommendations.  The availability of regulatory 68 
guidance on the pharmaceutical development of paediatric medicines is welcomed (EMA, 69 
2013), although detailed rationale for the recommendations is not provided.  Similar 70 
guidance on medicines for geriatric patients has not yet been published, although a number 71 
of activities are on-going including the development of a reflection paper (Agency, 2013; van 72 
Riet-Nales et al., 2016a). 73 
 74 
The International  Conference on Harmonisation (ICH) pharmaceutical development 75 
guideline (Q8 (R2)) states “in all cases, the product should be designed to meet patients’ 76 
needs and the intended product performance” (ICH, 2009).  Therefore when defining the 77 
Quality Target Product Profile (QTPP) and selecting an appropriate dosage form, it is 78 
important to consider patient requirements and how the product may be taken  alongside the 79 
complex technical challenges and feasibility of pharmaceutical development and 80 
manufacturing processes. In addition, the relative cost and supply of the product are 81 
important considerations..     82 
 83 
The criteria for the selection of an age-appropriate dosage form have previously been 84 
identified as being efficacy/ease of use, safety and patient access (Sam et al., 2012).  The 85 
aim of this review is to provide a comparison of different oral dosage forms according to 86 
these three criteria in order to assist  pharmaceutical product formulators to select and 87 
develop the most suitable product for paediatric and geriatric patients.  For the purposes of 88 
this review, it is assumed that formulators will have already considered active 89 
pharmaceutical ingredient (API) properties and other preformulation considerations, hence 90 
this topic will not be included.  Diseases to be treated would have an impact on the 91 
development of pharmaceutical products for children and older adults; however, a disease-92 
specific evaluation for developing age-appropriate formulations would render an entirely new 93 
angle of review. In this article, we discuss the general considerations in the selection of age-94 
appropriate formulations taking into account  the expected duration of treatment (short term 95 
versus long term) and severity of the condition when assessing the benefit risk balance of 96 
the excipients to be used within a formulation (EMA, 2013).   97 
 98 
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2. Factors to consider for paediatric/geriatric oral dosage form design  99 
Choice of formulation may be affected by the properties of the API, target age group and 100 
disease to be treated (Wang, 2015), as well as culture and geographical location.  In 101 
designing a drug product intended for use in paediatrics or older adults, all typical 102 
considerations of adult dosage form development apply.  As for any drug product, API 103 
properties which can impact the selection of dosage form include for example 104 
biopharmaceutical classification, physico-chemical properties, stability, dose and required 105 
release rate (Kuentz et al., 2016).  For instance, APIs with high solubility (BCS I and III) are 106 
generally more suitable for oral solutions and syrups compared to poorly soluble APIs, and 107 
mini tablets and oral films may not be appropriate for APIs which require high doses due to 108 
limitations in drug loading per unit dosage form.  Furthermore, API properties may influence 109 
the manufacturing method and processing route that may be applied to a particular dosage 110 
form (Leane et al., 2015).  The taste of an API should also be considered when selecting an 111 
oral dosage form, and approaches to minimise the interaction of an aversive-tasting API with 112 
taste receptors in the mouth should be utilised.  Formulations for paediatrics and older 113 
patients add complexity to the development process due to the diverse nature of the patient 114 
population, safety and compliance considerations.  Hence, additional factors need to be 115 
taken into account when developing products for these groups.   116 
 117 
As stated above, Sam et al. (2012) previously proposed a structured framework for 118 
assessing and balancing the benefits and risks of different pharmaceutical dosage forms for 119 
paediatric use in relation to 3 key criteria; efficacy/ease of use, safety and patient access 120 
(Sam et al., 2012).  The ease of use of a medicinal product (including dose flexibility), is one 121 
aspect that affects its overall acceptability to patients, and in this review, this broader 122 
concept of patient acceptability has been considered instead.  The factors to consider in 123 
relation to these 3 criteria are outlined in Table 1.  Patient acceptability is determined by the 124 
characteristics of the product and the user and may be defined as “an overall ability of the 125 
patient or caregiver (defined as ‘user’) to use a medicinal product as intended (or 126 
authorised)” (EMA, 2013; Kozarewicz, 2014). It can have a significant impact on patient 127 
adherence and therefore safe and effective therapy, and should be considered for all 128 
patients, including older adults.  A pharmaceutical product must have acceptable safety and 129 
a positive benefit risk profile and the safety profile of a formulation may differ according to 130 
the age of the patient. To enable patient access to the drug product, manufacturability, 131 
stability, supply chain and cost need to be considered.  Key features of oral dosage forms 132 
with respect to their patient acceptability, safety and access, based on pharmaceutical 133 
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development guidelines, the reflected literature and the authors’ experience are summarised 134 
in Table 2, and discussed in greater detail in the following sections.   135 
 136 
Table 1 Factors to consider for the selection of an oral dosage form 137 
Patient Acceptability 
Dosage considerations 
 
The ability of the formulation to be sub-divided without impact on 
the product's safety and efficacy to allow flexible and optimal 
dosing to the patient 
Dose preparation 
 
The requirement for any manipulation or measurement of a 
quantity of the formulation prior to administration.  
Ease of ingestion 
 
The ease with which the product may be taken by the patient, 
including aspects such as palatability, swallowability, size and 
quantity of solid dosage units, volume of liquid. 
Safety 
Acceptable tolerability 
and safety 
 
The product should not give rise to an unacceptably high risk of 
adverse effects, acute toxicity, organ toxicity or GI side effects, 
which are not directly caused by the API. 
 
Risk of mis-dosing 
 
The risk of administration of an incorrect dose, for example by 
incorrect handling, incorrect measurement and/or incorrect 
administration of the required dose. 
Access 
Stability The shelf-life of the product, including in-use if appropriate. 
Manufacturing and 
development 
complexity 
How complicated the required development process and 
manufacturing and packaging operations are, including the need 
to use specialised, non-routine processes. 
Supply chain 
 
How the product is stored and transported, including in 
resource-poor settings. 
Relative cost 
 
The estimated magnitude of cost of a dosage form compared to 
the other dosage forms, excluding API cost. 
 138 
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Table 2  Comparison of key features of oral dosage forms* 139 
 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Solution/ 
Syrup/ Drops  
High dose 
flexibility for 
solution/ syrup  
 
Some limitation 
with drops 
Require use 
of measuring 
device to 
measure and 
administer the 
required dose 
Easy to 
swallow  
 
Palatability 
may be an 
issue 
 
Volume needs 
consideration 
Multi dose 
containers 
require 
preservatives  
 
May require 
buffers, co-
solvents, 
flavours 
and/or 
sweeteners 
Risk of mis-
dosing due to 
incorrect 
handling and 
use of 
measuring 
device  
Generally less 
stable than 
solids 
 
Potential for 
microbiological 
contamination 
in-use 
 
Need to 
consider 
compatibility 
with primary 
packaging 
Non-complex 
development 
process 
 
Usually routine 
manufacturing 
and packaging 
process with 
standard 
equipment 
Bulky for 
transport and 
storage 
 
May need 
temperature 
control 
Low 
Emulsion High dose 
flexibility  
 
Require use 
of measuring 
device to 
measure and 
administer the 
required dose 
 
Require 
shaking prior 
to dosing to 
ensure 
homogeneity 
Easy to 
swallow  
 
Palatability 
may be an 
issue 
 
Volume needs 
consideration 
Multi dose 
containers 
require 
preservatives 
 
Require 
surfactants 
 
May require 
flavours 
and/or 
sweeteners 
As for 
"Solution/ 
Syrup", but 
with higher 
risk of mis-
dosing; 
requires 
shaking prior 
to measuring 
dose to 
ensure 
homogeneity 
and dose 
uniformity 
As for 
"Solution/ 
Syrup", but 
thermo- 
dynamically 
unstable 
Development 
and 
manufacturing 
process can 
be complex 
 
Usually routine 
packaging 
process with 
standard 
equipment 
As for 
"Solution/ 
Syrup" 
Medium/ 
high 
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 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Suspension  High dose 
flexibility  
 
Require use 
of measuring 
device to 
measure and 
administer the 
required dose 
 
Require 
shaking prior 
to dosing to 
ensure 
homogeneity 
Easy to 
swallow  
 
Palatability 
may be an 
issue 
 
Volume needs 
consideration  
 
Mouth feel 
needs to be 
considered to 
avoid a gritty 
sensation 
Multi dose 
containers 
require 
preservatives 
 
May require 
buffers, 
surfactants, 
flavours 
and/or 
sweeteners 
As for 
"Emulsion"  
As for 
"Solution/ 
Syrup", but 
may be less 
physically 
stable 
Development 
and 
manufacturing 
process can 
be complex, 
but less 
challenging 
than oral 
emulsions 
 
Usually routine 
packaging 
process with 
standard 
equipment 
As for 
"Solution/ 
Syrup" 
Medium 
Effervescent/ 
Dispersible 
tablet  
Low dose 
flexibility 
Require 
dissolution or 
dispersion in a 
suitable 
volume of 
water  
Easy to 
swallow  
 
Palatability 
may be an 
issue  
 
A large volume 
may be a 
challenge for 
young and 
older patients 
to swallow 
May require 
flavours 
and/or 
sweeteners 
 
Sodium, 
potassium 
and 
bicarbonate 
content to be 
considered 
Risk of mis-
dosing if full 
volume of the 
solution/ 
dispersion is 
not ingested, 
and/or 
residue not 
ingested 
Generally 
good stability, 
although can 
be sensitive to 
moisture so 
requires 
protective 
primary 
packaging 
 
Solutions/ 
dispersions 
have limited 
stability 
Non-complex 
development 
process 
 
Usually routine 
packaging 
process with 
standard 
equipment, but 
may need 
modified 
tooling and low 
humidity 
conditions 
 
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low/ 
medium 
FINALv1 with tables 2017_FL_JW  
 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Multi-
particulates/
Granules/ 
Sprinkles/ 
Powders  
Medium/High 
dose flexibility 
 
 
 
 
Requires 
appropriate 
use of device 
or packaging 
when 
measuring 
and/or 
administering 
dose 
 
Further 
preparation 
may be 
required if 
administered 
with food or 
beverage  
Easy to 
swallow  
 
Considered 
acceptable 
from 6 months 
when given 
with semi-solid 
food, from birth 
if dispersed in 
liquid  
 
Dose volume, 
texture 
(mouthfeel) 
and palatability 
require 
consideration  
 
Risk of 
aspiration or 
choking 
(when not 
dispersed) 
 
 
Risk of mis-
dosing for 
products 
requiring 
dose to be 
measured 
 
Risk of 
incomplete 
dosing if 
administered 
with food or 
beverage 
and mixture 
is not fully 
consumed 
 
Risk of 
constitution 
errors with 
powders for 
oral 
suspension 
Good stability 
 
Compatibility 
and stability 
with potential 
food or 
beverages 
should be 
verified (if 
labelled as 
such) 
Development 
and 
manufacturing 
complexity 
depends on 
technology 
used  
 
Usually routine 
packaging 
process with 
standard 
equipment 
 
Can also 
function as 
intermediate 
products in 
manufacture of 
other dosage 
forms 
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low/ 
medium 
Tablets Low dose 
flexibility 
No dose 
preparation 
required 
Difficult to 
swallow for 
neonates, 
infants and 
young children 
and older 
adults may 
have difficulty 
 
Risk of 
aspiration or 
choking 
 
Data on age 
vs. suitable 
tablet size 
required 
Low risk of 
incorrect use 
and mis-
dosing 
 
Greater risk if 
tablet 
manipulated  
Good stability Non-complex 
development 
process 
 
Usually routine 
manufacturing 
and packaging 
process with 
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low 
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 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Size and shape 
need 
consideration 
for ease of 
swallowing 
 
Limited 
organoleptic 
issues 
standard 
equipment 
Hard gelatin 
capsules  
Low dose 
flexibility 
No dose 
preparation 
required when 
swallowed 
whole 
 
Further 
preparation 
required if 
capsule 
contents 
administered 
with food or 
beverage 
Difficult to 
swallow for 
neonates, 
infants and 
young children, 
and older 
adults may 
have difficulty 
 
Size needs 
consideration 
for ease of 
swallowing 
 
Limited 
organoleptic 
issues 
 
Risk of 
aspiration or 
choking 
 
Risk of 
gelatin shell 
sticking to 
the mucosa 
of the 
oesophagus 
leading to 
retention 
 
Gelatin may 
not be 
accepted by 
some 
cultures/ 
lifestyles but 
alternatives 
available  
Low risk of 
incorrect use 
and mis-
dosing  
Good stability  Non-complex 
development 
process 
 
Usually routine 
manufacturing 
and packaging 
process with 
standard 
equipment 
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low 
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 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Soft gelatin 
capsules 
("Softgels") 
(excluding 
chewables) 
 
Low dose 
flexibility 
No dose 
preparation 
required 
Difficult to 
swallow for 
neonates, 
infants and 
young children, 
and older 
adults may 
have difficulty 
 
Limited 
organoleptic 
issues 
 
As for "hard 
gelatin 
capsules" 
 
Potential risk 
of chewing 
 
Low risk of 
incorrect use 
and mis-
dosing 
Potentially less 
stable than 
tablets; may 
be sensitive to 
high 
temperature 
and humidity 
Requires 
specialist 
development 
and 
manufacturing 
processes 
 
Usually routine 
packaging 
process with 
standard 
equipment 
Transport 
and storage 
more 
favourable 
compared to 
liquids  
 
May be 
unsuitable for 
storage at 
high 
temperatures 
and 
humidities.  
High 
Mini-tablets 2 
(1 - 4 mm)  
Medium dose 
flexibility 
May require 
counting or 
measuring 
device, or 
appropriate 
packaging for 
measuring/ 
administering 
multiple mini-
tablets 
 
Handling may 
be difficult for 
older patients 
with poor 
manual 
dexterity  
Easier to 
swallow than 
conventional 
sized tablets 
 
Limited 
organoleptic 
issues 
Potential risk 
of choking or 
aspiration 
(especially in 
young 
children (< 2 
years), if 
coated) 
Risk of mis-
dosing where 
multiple mini 
tablets are 
required per 
dose 
 
Good stability Non-complex 
development 
process 
 
Usually routine 
manufacturing 
and packaging 
process with 
standard 
equipment 
 
Content 
uniformity may 
be a challenge 
Transport 
and storage 
more 
favourable 
compared to 
liquids  
 
Low 
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 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
Oro- 
dispersible 
tablet/ Melt  
Low dose 
flexibility 
No dose 
preparation 
required 
 
May be taken 
without water 
Easier to 
swallow than 
conventional 
tablets  
 
Taste and 
mouth feel 
(grittiness) are 
main 
considerations 
 
Potential risk 
of choking or 
aspiration 
 
May require 
flavours 
and/or 
sweeteners 
 
Low risk of 
incorrect use 
and mis-
dosing 
Good stability 
but may 
require 
moisture 
protective 
packaging 
Complexity 
depends on 
technology 
used 
 
Routine 
manufacturing 
process with 
standard 
equipment 
(compressed 
ODTs) or 
specialist 
process and 
equipment 
(lyophilisates)  
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low - 
high 
Chewable 
dosage 
forms  
Low dose 
flexibility 
No dose 
preparation 
required 
Should be 
chewed and 
not swallowed  
 
Not suitable for 
patients without 
teeth or those 
with limited 
chewing ability  
 
Palatability 
may be an 
issue  
 
Risk of 
choking or 
aspiration 
 
Risk of 
intestinal 
obstruction if 
swallowed 
intact or 
partially 
chewed 
 
May require 
flavours 
and/or 
sweeteners 
Low risk of 
mis-dosing 
Good stability 
but may 
require 
moisture 
protective 
packaging 
Complexity 
depends on 
technology 
used 
 
Routine 
manufacturing 
process with 
standard 
equipment 
(tablets) or 
specialist 
process and 
equipment 
(deposited 
Transport 
and storage 
more 
favourable 
compared to 
liquids 
Low/ 
medium. 
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 Patient Acceptability1 Safety Access 
Feature/ 
Dosage 
form 
 
 
Dosage 
considerations 
Dose 
preparation 
Ease of 
ingestion 
(Organoleptic 
suitability) 
Acceptable 
tolerability 
& safety 
Risk of mis-
dosing 
Stability 
(shelf life & 
in-use) 
Complexity of 
development 
and 
manufacture 
Supply 
chain 
Relative 
cost 
formulations 
and softgels) 
Oral films 
(dispersible) 
Low dose 
flexibility 
No dose 
preparation 
required  
 
May be taken 
without water 
 
Handling of 
small films 
may be 
difficult for 
older patients 
with poor 
manual 
dexterity 
Easy to 
swallow  
 
May require 
plasticisers, 
flavours 
and/or 
sweeteners 
Low risk of 
mis-doing 
Good stability 
but require 
moisture 
protective 
packaging 
Requires 
specialist 
development, 
manufacturing 
and packaging 
processes 
 
 
Transport 
and storage 
more 
favourable 
compared to 
liquids  
 
Medium/ 
high 
* Based on pharmaceutical development  guidelines, reflected literature and the authors’ experience 140 
1 See also Table 3 for literature evidence of patient acceptability 141 
2 Mini tablets are defined as being 1-3 mm in diameter, however studies evaluating the acceptability of 4 mm mini tablets are included 142 
 143 
 144 
FINALv1 with tables 2017_FL_JW  
3. Acceptability  145 
Oral dosage forms may be divided into those which provide flexible doses, such as liquids 146 
and multiparticulates, and those which provide unit doses, such as tablets and capsules.  147 
Each have advantages and disadvantages for the user which should be carefully considered 148 
during paediatric and geriatric medicine development (Sam et al., 2012; van Riet-Nales et 149 
al., 2016b), as discussed below. 150 
 151 
The EMA reflection paper published in 2005 provided a matrix proposing the applicability of 152 
various dosage forms in children of different ages (CHMP, 2006).  However, the evaluation 153 
was based on anecdotal evidence only and the matrix was not suggested to be used as 154 
recommendations for paediatric formulation development, although it may have been used 155 
as such (van Riet-Nales et al., 2016a).  A decade later, reports on the acceptability of some 156 
of the dosage forms in children have been published, yet evidence is sparse.  A detailed 157 
evaluation of evidence of acceptability of oral paediatric medicines can be found in a recently 158 
published article (Mistry et al., 2017), and a recent systematic literature review analysed 159 
dosage form design features that can affect patients’ acceptability or preference in both 160 
paediatric and adult populations (Drumond et al., 2017).  In the current review, studies that 161 
generated evidence in dosage form acceptability are presented in Table 3 according to 162 
different age groups including children and older adults.  Crucially, these studies are based 163 
on published literature evidence of patient or caregiver reported acceptability of dosage 164 
forms, rather than reasonable judgements of suitability, or the availability of licensed 165 
products.  In this review, the age range of children were divided into sub-groups according to 166 
the ICH guideline (ICH, 2001). For the older population, many factors other than arbitral age 167 
affect their overall ability; however, it has been suggested to sub-divide the population into 168 
the “early-old” from 65 to 74 years, the “middle-old” from 75 to 84 years and the “late-old” 169 
starting from 85 years of 170 
age (Swanlund, 2010). For the purpose of this review, the sub-division of the older 171 
population was not included in Table 3, due to the limited studies conducted in this patient 172 
population compared to those in children.   173 
 174 
Acceptability is defined as the end-user ability and willingness to use a medicinal product 175 
[16], however studies reporting on comparative preferences between different formulations 176 
have also been included.  Whilst comparative patient preferences between formulations, to 177 
some extent, provide an indirect indication of patient acceptability, it should be noted that 178 
they have limitations in guiding pharmaceutical development.  Preference would likely be of 179 
more importance for consumer health and over-the-counter medicinal products where more 180 
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than one option may be available to the consumer. This is often not the case for New 181 
Chemical Entities (NCE’s).  There are significant methodological differences and 182 
complexities in published studies reporting medicines acceptability in children and the 183 
elderly. This may have contributed to the seemingly conflicting results for some dosage 184 
forms. 185 
 186 
Oral liquids are one of few formulation types typically considered suitable from birth (EMA, 187 
2013) and the provision of dose flexibility and ease of swallowing with liquid products are 188 
important advantages, both for children and geriatric patients.  Palatability is the critical 189 
determinant of acceptability, and various studies have reported measures of this specific 190 
parameter when evaluating liquid formulations (Angelilli et al., 2000; Cote et al., 2002; Herd 191 
and Salehi, 2006; Schwartz, 2000; Tolia et al., 2005).  This can present a major limitation of 192 
these dosage forms, since many APIs and excipients are known to have an aversive taste, 193 
and limited taste-masking strategies can be applied to liquids (Cram et al., 2009).  The poor 194 
taste of liquid medicines has shown to be a major barrier for older patients with dysphagia 195 
(Kelly et al., 2010) and in children (Venables et al., 2015).  Dose volume is another primary 196 
consideration in the acceptability of liquids.  A commonly cited recommendation for 197 
paediatrics is a target volume of ≤ 5 mL for children under 5 years and ≤ 10 mL for children 198 
of 5 years and older (EMA, 2013) (Organisation, 2012).  However, no studies have been 199 
identified which correlate the relationship between dose volume and patient acceptance, and 200 
little guidance is available for older patients.  Similarly, there is little evidence to determine 201 
the relationship between product acceptability and other important attributes, such as 202 
viscosity, particle size, and use of delivery devices (Mistry et al., 2017).  The effect of 203 
viscosity and consistency of dietary liquids on swallowing performance in dysphagic patients 204 
has been investigated (Dantas et al., 1990; Steele and Van Lieshout, 2004; Troche et al., 205 
2008); however, the impact on acceptability and safety of liquid medicines in older patients 206 
has scarcely been studied.  207 
 208 
Dispersible and effervescent tablets are dissolved in water prior to administration, therefore 209 
the acceptability of these dosage forms may be affected by similar factors as liquids.  210 
However, directly reported evidence is scarce in both the paediatric and geriatric populations 211 
(Table 3).  Numerous sources highlight that large volumes of water that may be required to 212 
dissolve these tablets can be problematic for children and older patients.  Two referenced 213 
studies involved administration of dispersible/effervescent tablets to children using small 214 
amount of water (a few drops or 5 mL) (Nasrin et al., 2005; Winch et al., 2006).  Similar to 215 
liquid formulations, the effect of administration volume together with other attributes of the 216 
dosage form (e.g. palatability) on patient acceptance needs further investigation. 217 
FINALv1 with tables 2017_FL_JW  
 218 
The acceptability of tablets (> 5 mm) and capsules in children and older adults is largely 219 
determined by the ability to swallow the dosage form intact.  Even for children of the same 220 
age, this ability varies considerably between individuals, and is affected by their disease 221 
status and available training.  Children with HIV as young as 3 years were able to swallow 222 
antiretroviral tablets, whereas one-third of adolescents were found to have problems 223 
swallowing tablets (Hansen et al., 2008; Nahirya-Ntege et al., 2012; Yeung and Wong, 224 
2005).  Nevertheless, studies suggest that for children of older age groups (12 years and 225 
over), tablets are a more preferred choice of medicine compared to powder and liquid 226 
formulations (MacDonald et al., 2003; McCrindle et al., 1997; Nahirya-Ntege et al., 2012).  In 227 
a recent study, tablets were reported to be the preferred solid oral dosage form amongst 228 
adolescents and their caregivers (Ranmal et al., 2016). There is limited evidence available 229 
linking tablet size and shape to ability of swallowing in different age groups (Kokki et al., 230 
2000; Meltzer et al., 2006).  Difficulty in swallowing tablets in older adults, especially those 231 
with dysphagia has been reported (Schiele et al., 2013).  Capsules were reported to have a 232 
greater tendency of prolonged oesophagus transit compared to tablets in older patients and 233 
oesophageal retention can occur in these patients even when administrated with a large 234 
amount of fluid (Bailey et al., 1987; Perkins et al., 1999).  A better understanding of the 235 
optimum dimensions across age groups, as well as the influence of physical characteristics 236 
(such as shape or surface coating) would be highly valuable for patient-centred medicine 237 
development.  238 
 239 
Orally disintegrating tablets (ODTs) and chewable tablets are considered to be convenient to 240 
take especially without the need for water.  Palatability and retention time in the mouth are 241 
important aspects that may influence their acceptability; however, these dose forms have not 242 
been evaluated extensively in children and older adults.  A recent study assessing end-user 243 
perceptions of oral dosage forms found a preference for chewables amongst school children, 244 
adolescents and their caregivers (Ranmal et al., 2016). In older patients with dysphagia, 245 
ODTs proved to be easier to swallow (Carnaby-Mann and Crary, 2005) and were well 246 
accepted for the treatment of Parkinson’s disease, hypertension and hypoglycaemia (Fukui-247 
Soubou et al., 2011; Koh et al., 2008; Nausieda et al., 2005).  248 
 249 
Emerging evidence suggests that many children and their caregivers often show higher 250 
acceptability to solid oral dosage forms compared to liquids, if these are designed to be 251 
suitable in relation to the capabilities of the child.  This is illustrated through the emergence 252 
of mini-tablets which have been studied in neonates and infants, and reported to show better 253 
acceptance than liquids (Klingmann et al., 2015b; Klingmann et al., 2013b; Spomer et al., 254 
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2012a; van Riet-Nales et al., 2013).  Administration of multiple mini-tablets has recently been 255 
studied (Kluk et al., 2015), however the effects of larger quantities and long-term 256 
acceptability requires further understanding.  In addition, evidence of chewing was seen in 257 
all studies referenced.  This is an important consideration for certain APIs or delivery 258 
systems, where palatability, safety, and/or bioavailability concerns may arise if the integrity 259 
of the dosage form is compromised.  The use of mini-tablets accompanied by an electronic 260 
dispensing device was considered to be favourable in patients with Parkinson’s disease for 261 
the potential of easy swallowing and flexible dosage (Bredenberg et al., 2003).  Further 262 
investigation of the acceptability of this emerging dosage form in older patient groups needs 263 
research attention.  264 
 265 
Multiparticulate formulations include powders, granules and pellets, and offer alternative 266 
options for administration, ranging from direct administration into mouth, to sprinkling onto 267 
food or mixing with drink.  They are generally considered to be suitable from six months of 268 
age, when infants start to feed on semi-solid foods (EMA, 2013).  A relatively larger numbers 269 
of studies have investigated their acceptance in children compared to other oral dosage 270 
forms; however evidence from these studies is too heterogeneous in nature to support an 271 
overall consensus, partially due to the diversity of methodologies applied.  The use of 272 
sprinkles for administration of micronutrients in young children (0-5 years) has been 273 
investigated, yet mixed results in acceptability have been reported (de Pee et al., 2007; 274 
Jefferds et al., 2010; Kounnavong et al., 2011).  Acceptability was often linked to whether the 275 
sprinkles changed the colour, texture and smell of food.  As mentioned previously, sprinkles 276 
were generally more acceptable over oral liquids (e.g. drops, solution and syrup) in children 277 
of age ranging from 5 months to 16 years, although texture and viscosity of vehicle if used, 278 
can have an impact (Cloyd et al., 1992; Geltman et al., 2009; Lopez et al., 2016; Zlotkin et 279 
al., 2003).  Particle size can be a critical aspect affecting acceptability of multiparticulates.  280 
The FDA recommends a target particle (bead) size of 2.5 mm for multiparticulate products to 281 
be labelled for sprinkle administration (Administration, 2012).  Studies suggest that oral 282 
grittiness of multiparticulates increases with increasing particle sizes (Kimura et al., 2015; 283 
Lopez et al., 2016); although evidence still needs to be established, the particle size 284 
recommended by FDA might not render adequate mouth-feel and might affect patient 285 
acceptability.  Evidence of the acceptability of multiparticulates in older adults is limited.  A 286 
recent study investigated acceptability of oral flexible dosage forms in older patients 287 
attending community pharmacies and found that granules were the least acceptable (Liu et 288 
al., 2016).  The main reason for not being favourite in this patient group was the concern for 289 
the effect of granules on food when mixed together.   290 
 291 
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Oral films are relatively new developments in oral formulations for paediatric and geriatric 292 
use.  Similar to ODTs they are convenient to use and can be taken without water; however, 293 
again, investigations in their use in children and older adults are still limited.  Rodd et al. 294 
reported that oral filmstrips were more acceptable in infants (aged 1.9-4.3 weeks) and their 295 
parents compared to oral drops (Rodd et al., 2011).  The reasons for this were attributed to 296 
accurate dosing and easier administration for the film formulation.  297 
 298 
In general as shown in Table 3, there is a distinct lack of information to enable age 299 
appropriate dosage form selection to be based on patient acceptability data.  Although 300 
regulatory guidance indicates oral liquids and powders/granules administered as a liquid 301 
preparation are acceptable for the whole (paediatric) population from birth, there are limited 302 
data on the effect that volume, viscosity and particle size (in suspensions) can have on 303 
acceptability in different age groups.  Similarly for solid oral dosage forms, there are still 304 
many unknowns in terms of for example, how multiple mini tablets and tablet size and shape 305 
can impact patient acceptability.  Furthermore, there are examples where consensus on 306 
acceptability of a particular dosage form in a specific age group has not been reached 307 
between different studies, for example oral liquids in infants and toddlers, and mini tablets in 308 
pre-school aged children.  However it is not known if this is due to differences in 309 
methodologies and/or other factors such as taste.  Hence, although evidence is emerging in 310 
this area of research, it is still necessary to consider the patient acceptability of products on 311 
a case by case basis.  312 
 313 
In older patient populations, considerably less evidence is available on the acceptability of 314 
medicines compared to children. There is a large variation in the quality of research 315 
conducted in this patient population and a lack of consistency in study methodologies. 316 
However there are examples of evidence emerging in recent years, such as the use of ODTs 317 
in patients with Parkinson’s disease and hypertension  (Fukui-Soubou et al., 2011; Nausieda 318 
et al., 2005).  Whilst age is often used to sub-divide the paediatric population, more factors 319 
could affect the acceptability of medicines in older patients;  frailty, co-morbidity, 320 
polypharmacy, and  visual/cognitive impairments. The diseases to be treated may have a 321 
greater impact on developing appropriate formulations for older patients than for children, 322 
due to disease effects on patient characteristics, dose regimens, therapeutics/side effects 323 
and adherence.  Overall, there are some similarities in acceptability considerations for 324 
paediatric and geriatric patients, for example  difficulties in swallowing tablets and capsules 325 
which may impact  dosage form selection. However, it should be noted that distinct 326 
differences exist between the two patient populations (Liu et al., 2014).  Similar issues in 327 
medication acceptability might have different impacts in children and older patients. For 328 
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example, understanding the need for medication adherence  and subsequent co-operation 329 
may differ in the two patient groups, and the taste of a medicine might influence the 330 
willingness (or unwillingness) to take a medicinal product in different ways.331 
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Table 3 Literature-based evidence for patient acceptability of oral dosage forms according to age 332 
Dosage form 
Preterm 
newborn 
infants 
Term newborn 
infants 
(od-28d) 
Infants and toddlers 
(1m-2y) 
Pre-school 
children 
(2-5y) 
School children 
(6-11y) 
Adolescents 
(12-18y) 
Older adults (≥ 
65y) 
Liquid: Solution/Syrup/Drops/ 
Suspension/Emulsion 
+ (Klingmann 
et al., 2015a) 
+ (Cohen et 
al., 2009; 
Klingmann et 
al., 2015a) 
±(Strehle et 
al., 2010) 
- (Rodd et al., 
2011) 
+ (Cohen et al., 
2009; Geltman et 
al., 2009; 
Klingmann et al., 
2013a; Spomer et 
al., 2012; van Riet-
Nales et al., 2013) 
± (Dagan et al., 
1994; Kekitiinwa et 
al., 2016; Nahirya-
Ntege et al., 2012; 
Scolnik et al., 2002) 
- (van Riet-Nales et 
al., 2015; Zlotkin et 
al., 2003) 
 
+(Cohen et al., 
2009; Jacobsen 
et al., 2015b; 
Klingmann et al., 
2013a; Moniot-
Ville et al., 1998; 
Mulla et al., 2016; 
Spomer et al., 
2012) 
±(Kekitiinwa et 
al., 2016; 
Nahirya-Ntege et 
al., 2012; Scolnik 
et al., 2002) 
- (van Riet-Nales 
et al., 2015; 
Verrotti et al., 
2012) 
+ (Bekele et al., 
2014; Cohen et 
al., 2009; 
Jacobsen et al., 
2015b; Moniot-
Ville et al., 1998; 
Mulla et al., 2016) 
±(Nahirya-Ntege 
et al., 2012) 
-(Cloyd et al., 
1992; Verrotti et 
al., 2012) 
+ (Cohen et al., 
2009) (Bekele et 
al., 2014) 
±(Nahirya-Ntege 
et al., 2012) 
-(Cloyd et al., 
1992) 
 
0 
Effervescent/Dispersible 
tablet 
0 0 
+ (Nasrin et al., 
2005b; Winch et al., 
2006) 
+ (Nasrin et al., 
2005b; Winch et 
al., 2006) 
0 0 
+(Phillips et 
al., 1992) 
±(Bayer et al., 
1988; Sebert 
et al., 1995) 
Multiparticulates/Granules/ 
Sprinkles/Powders 
0 0 
+ (Geltman et al., 
2009; Munck et al., 
2009b; van Riet-
Nales et al., 2013; 
Zlotkin et al., 2003) 
±(Kekitiinwa et al., 
2016) 
+(Munck et al., 
2009b; Verrotti et 
al., 2012) 
±(Kekitiinwa et 
al., 2016; 
Patchell et al., 
2002) 
+(Cloyd et al., 
1992; Verrotti et 
al., 2012) 
±(Patchell et al., 
2002) 
-(Kekitiinwa et al., 
2016) 
+(Cloyd et al., 
1992) 
±(Patchell et al., 
2002) 
-(Kekitiinwa et 
al., 2016; 
McCrindle et al., 
1997) 
+ (den Uyl et 
al., 2010) 
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- (van Riet-Nales et 
al., 2015) 
- (van Riet-Nales 
et al., 2015) 
Tablets (≥ 5 mm) 0 0 
+ (Kokki et al., 
2000) 
±(Coleman et al., 
2002; Nahirya-
Ntege et al., 2012) 
 
+ (Beck et al., 
2005; El Edelbi et 
al., 2015a; 
Jacobsen et al., 
2015a; Kekitiinwa 
et al., 2016; 
Kokki et al., 
2000; 
Kreeftmeijer-
Vegter et al., 
2013) 
±(Coleman et al., 
2002; Nahirya-
Ntege et al., 
2012) 
 
+ (Beck et al., 
2005; Bekele et 
al., 2014; El 
Edelbi et al., 
2015a; Jacobsen 
et al., 2015a; 
Kekitiinwa et al., 
2016; Kokki et al., 
2000; 
Kreeftmeijer-
Vegter et al., 
2013; Lottmann et 
al., 2007b; 
MacDonald et al., 
2003; McCrindle 
et al., 1997; 
Meltzer et al., 
2006) 
±(Coleman et al., 
2002; Nahirya-
Ntege et al., 
2012) 
 
+ (Bekele et al., 
2014; El Edelbi 
et al., 2015a; 
Jacobsen et al., 
2015a; 
Kekitiinwa et al., 
2016; 
Kreeftmeijer-
Vegter et al., 
2013; Lottmann 
et al., 2007b; 
MacDonald et 
al., 2003; 
McCrindle et al., 
1997; Weinberg 
and Naya, 2000) 
±(Coleman et 
al., 2002; 
Nahirya-Ntege 
et al., 2012) 
- (Hansen et 
al., 2008) 
+(Perkins et 
al., 1994) 
±(Brotherman 
et al., 2004; 
Sebert et al., 
1995) 
-(Carnaby-
Mann and 
Crary, 2005; 
Nausieda, 
2005; Phillips 
et al., 1992; 
Schiele et al., 
2015) 
Capsules  0 0 
-(Munck et al., 
2009a) 
+ (Beck et al., 
2005; El Edelbi et 
al., 2015b; Garvie 
et al., 2007; 
Jacobsen et al., 
2015a; 
Mekmullica and 
Pancharoen, 
2003) 
±(Babbitt et al., 
1991) 
+ (Beck et al., 
2005; Bekele et 
al., 2014; El 
Edelbi et al., 
2015b; Garvie et 
al., 2007; 
Jacobsen et al., 
2015a; 
Mekmullica and 
Pancharoen, 
2003) 
+ (Bekele et al., 
2014; El Edelbi 
et al., 2015b; 
Garvie et al., 
2007; Jacobsen 
et al., 2015a) 
±(Babbitt et al., 
1991) 
-(Bailey et al., 
1987; Perkins 
et al., 1994; 
Schiele et al., 
2015) 
±(Bayer et al., 
1988) 
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- (Czyzewski et 
al., 2000; Munck 
et al., 2009a) 
 
±(Babbitt et al., 
1991) 
- (Czyzewski et 
al., 2000) 
 
Mini-tablets1 (1-4 mm) 
+ (Klingmann 
et al., 2015a) 
+ (Klingmann 
et al., 2015a) 
+ (Klingmann et al., 
2013a; Spomer et 
al., 2012; van Riet-
Nales et al., 2013; 
van Riet-Nales et 
al., 2015) 
±(Kekitiinwa et al., 
2016) 
- (Van de Vijver et 
al., 2011) 
+ (Klingmann et 
al., 2013a; 
Spomer et al., 
2012; van Riet-
Nales et al., 
2015) 
± (Kekitiinwa et 
al., 2016; Kluk et 
al., 2015) 
- (Thomson et 
al., 2009) 
-(Kekitiinwa et al., 
2016) 
-(Kekitiinwa et 
al., 2016) 
0 
Oro-dispersible tablet 0 
±(Valovirta 
and Scadding, 
2009) 
±(Valovirta and 
Scadding, 2009) 
±(Valovirta and 
Scadding, 2009) 
+ (Cohen et al., 
2005; Lottmann et 
al., 2007a) 
±(Valovirta and 
Scadding, 2009) 
+(Lottmann et 
al., 2007a) 
+ (Carnaby-
Mann and 
Crary, 2005; 
Fukui-Soubou 
et al., 2011; 
Koh et al., 
2008; 
Nausieda et 
al., 2005) 
Chewable tablet 0 0 0 0 
+(Bukstein et al., 
2003) 
0 
+ (den Uyl et 
al., 2010) 
Oral film 0 
- (Rodd et al., 
2011) 
0 0 0 0 0 
Key: 333 
+ acceptable; - not acceptable; ± both acceptable and not acceptable data reported; 0 no evidence found; reference number provided in parentheses. 334 
 335 
In cases where no clear definition of “acceptability” was given in the article, “acceptable” of a formulation was defined as > 70% of participants support the 336 
acceptability of a product or a product scores > 70% of the scale used in the study, in analogy to Mistry et al [18]. 337 
1 Mini tablets are defined as being 1-3 mm in diameter, however studies evaluating the acceptability of 4 mm mini tablets are included. 338 
 339 
FINALv1 with tables 2017_FL_JW  
The data presented in the table was based on a literature search on Pubmed, Scopus and Embase, from the beginning of the source to May 2017. The 340 
search terms included a combination of “elderly, older adults, aging, ageing, geriatric, paediatric, pediatric, children, infant, newborn, adolescent, teens, youth, 341 
teenagers” AND “oral formulation, oral dosage form” AND “Satisfaction, acceptance, preference,  approval, acceptability, swallow, palatability”.  342 
 343 
 344 
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4. Safety  345 
Patient safety is of great importance, and when selecting a dosage form, the safety and 346 
tolerability of the dosage form type and the required excipients used must be assessed, in 347 
particular for the younger and older age groups.  In addition, the potential for mis-dosing 348 
must be considered.   349 
 350 
Excipients have different functional roles within a formulation and their selection is therefore 351 
closely linked to dosage form.  Although they are generally considered to be 352 
pharmacologically inactive, excipients may cause adverse effects or may affect the exposure 353 
of a drug (CHMP, 2006).  During infancy and childhood there are significant developmental 354 
changes including the maturation of metabolic pathways and organ systems which can 355 
impact the way in which an excipient is handled (Benedetti et al., 2005; CHMP, 2006).  For 356 
example, immature alcohol dehydrogenase can lead to accumulation of ethanol in neonates 357 
and infants (Zuccotti and Fabiano, 2011), and there is the potential for propylene glycol 358 
toxicity in children below 4 years due to limited metabolic capacity and renal function (EMA, 359 
2014a).  In addition, the use of benzoates and benzoic acid is a concern in neonates, where 360 
an accumulation of unmetabolised benzoic acid may lead to the displacement of bilirubin 361 
from albumin leading to hyperbilirubinaemia (EMA, 2014b).  The potential impact of 362 
excipients on organ development in neonates, infants and young children should also be 363 
considered.  For example, there have been safety concerns regarding possible endocrine-364 
disrupting effects of the preservative propyl paraben, although a permitted daily exposure 365 
limit of 2 mg/Kg body weight for both adult and paediatric patients has been calculated 366 
based on juvenile rat toxicity data (EMA, 2015).  A recent re-review of animal reproductive 367 
and developmental toxicity studies has led to a new temporary acceptable daily intake (ADI) 368 
for sorbic acid and its potassium salts of 3 mg/Kg body weight (EFSA, 2015). 369 
 370 
During the aging process there are changes in metabolising enzymes as well as a reduction 371 
in liver perfusion and renal function (Perrie et al., 2012)].  Therefore, it is conceivable that 372 
accumulation of excipients may occur in older patients, leading to toxicity and adverse 373 
effects.  A list of such excipients are summarised in a review (Breitkreutz and Boos, 2007). 374 
As with evidence of acceptability, there appears to be a considerable lack of information 375 
regarding the safety profiles of pharmaceutical excipients in older adults compared to 376 
children, and hence this requires  further research attention.  377 
 378 
In addition to the preservatives and co-solvents highlighted above, other excipients which 379 
have been reported in the literature to have potential risks include sweeteners (e.g. 380 
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saccharin, aspartame, sorbitol), solubilising agents (surfactants) (e.g. polysorbate) and 381 
flavourings (Ernest et al., 2007; Ursino et al., 2011).  The latter can be complex mixtures, the 382 
exact composition of which is often not known (especially natural flavours).  Risk of allergies 383 
and sensitization as well as toxicity of the flavouring including the solvent or carrier used 384 
should be considered (Walsh et al., 2014).   385 
 386 
Formulators also need to consider the salt and electrolyte content of the dosage form.  For 387 
example, formulations containing high levels of sodium or potassium may not be suitable for 388 
patients with renal insufficiency (CHMP, 2006), and high salt (sodium chloride) intake has 389 
been identified as a risk factor for the development of hypertension in adults (Nutrition), 390 
2003).  Indeed, adult patients prescribed sodium-containing effervescent, dispersible and 391 
soluble formulations have been found to experience an excess of cardiovascular events 392 
compared with patients on non-sodium formulations of the same drugs, these events being 393 
largely driven by an increased risk of stroke and hypertension (George et al., 2013).   394 
 395 
Multi-dose oral liquids such as solutions, syrups, emulsions and suspensions generally 396 
require the inclusion of a preservative system to maintain microbiological quality throughout 397 
the product shelf-life.  The exception to this is traditional syrups which contain high 398 
concentrations (60 - 80 %) of sucrose, and hence low water activity.  However, chronic 399 
administration of oral liquid medicines containing sucrose have been found to increase the 400 
incidence of dental caries and gingivitis in children (Roberts and Roberts, 1979).  Therefore, 401 
due to the cariogenic and glycogenic properties of sucrose, "sugar-free" syrups containing 402 
sugar substitutes such as sugar alcohols (polyols) (e.g. sorbitol, maltitol, glycerol), are more 403 
commonly developed, which require preservatives.  It should be noted that formulations 404 
containing high levels of polyols may potentially have laxative effects (Walsh et al., 2014) 405 
and it has been reported that a number of these osmotically active excipients can have an 406 
impact on the absorption of some drugs, although the mechanism is not known (Chen et al., 407 
2013). 408 
 409 
Oral liquids commonly require the inclusion of functional excipients that may have 410 
unfavourable safety and toxicity characteristics for young and older patients, as described 411 
above, depending on their level of use and duration of treatment.  For example, oral 412 
solutions may require a co-solvent (e.g. ethanol, propylene glycol, glycerol) to increase the 413 
solubility of the API, and buffers (electrolytes) are often employed to optimise the pH of the 414 
solution formulation to maintain the solubility of the API.  The control of pH is also required 415 
for all preserved oral liquids to ensure optimal preservative activity.  Frequent use of low pH 416 
oral medicines has been reported to potentially cause dental erosion in children, especially 417 
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when the pH is below 5.5 (Taji and Seow, 2010).  Oral suspensions and emulsions are 418 
fundamentally unstable and salts including buffers, and surfactants such as dispersing and 419 
emulsifying agents (e.g. polysorbates) are employed to enhance the physical properties of 420 
these formulations.   421 
 422 
As highlighted above, palatability is one of the main elements of the patient acceptance of an 423 
oral medicinal product (EMA, 2013) and since many APIs have an unpleasant taste, it is 424 
likely that the majority of oral dosage forms require the application of taste masking.  Solid 425 
oral dosage forms that are swallowed intact such as tablets or multiparticulates may have a 426 
non-functional coat applied which provides a barrier between the API and taste receptors in 427 
the mouth and throat.  Similarly, hard and soft capsules tend to have minimal taste by virtue 428 
of the materials with which the capsule shells are made (for example gelatin, hypromellose 429 
or starch derivatives).  In contrast, oral liquids, effervescent, (oro) dispersible and chewable 430 
dosage forms, and oral films, generally require the utilisation of taste masking techniques to 431 
improve their palatability.  Sensory based taste masking approaches using sweeteners 432 
and/or flavouring agents are commonly used for oral dosage forms (Walsh et al., 2014).  433 
However, as indicated above, sweeteners and flavourings are excipient groups for which 434 
some safety concerns have been raised.  Older patients often take multiple medications 435 
(polypharmacy) and hence there is the potential risk of additive excipient effects in these 436 
patients. 437 
 438 
Whilst the risk associated with required excipients is relatively higher for liquid products than 439 
oral solid products, choking is another potential safety risk in using oral medicines for 440 
paediatric and older patients.  Dysphagia is a common condition in older adults due to for 441 
example a weak tongue and poor control of muscles (Perrie et al., 2012).  In addition, 442 
nervous system disorders and some medications can have a negative impact on patient 443 
swallowing ability including reduced saliva flow (Stegemann et al., 2012).  This can result in 444 
older adults having difficulty in swallowing conventional solid oral dosage forms, with a 445 
potential risk of choking.  The ability of children to swallow solid oral dosage forms such as 446 
tablets is dependent on the developmental stages of individual child as discussed in the 447 
previous section.  Inappropriate use of these formulations may pose the risk of choking in 448 
children, for example incidents of coughing were observed in young children when 449 
administered coated mini-tablets (Klingmann et al., 2013b).  It is possible that the size and 450 
shape of tablets/capsules and the volume of multiparticulates may affect the risk of choking, 451 
although no clear evidence of this could be found in the public domain.  452 
 453 
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Medicines that are in a liquid format such as oral solutions, suspensions, emulsions, and 454 
constituted effervescent and dispersible dosage forms may have a lower risk of choking 455 
compared to solid oral dosage forms.  However, low viscosity liquids increase 456 
aspiration/penetration risks in older patients with dysphagia (Dantas et al., 1990).  Indeed, it 457 
has been found that the risk of aspiration of a liquid in patients with dysphagia is affected by 458 
many characteristics of the liquid, including viscosity, texture, volume and delivery device.  459 
These factors need to be considered when developing liquid-form medicines for paediatric 460 
and older patients. 461 
 462 
The use of solid oral dosage forms that disintegrate in the mouth or may be chewed can 463 
mitigate the risk of choking.  However, it should be noted that ODTs were shown to have the 464 
same risk of choking as conventional tablets in patients with dysphagia (Carnaby-Mann and 465 
Crary, 2005).  With chewable tablets, there is a risk of intestinal obstruction should the tablet 466 
be swallowed or only partially chewed (Gupta et al., 2013).  In addition, care should be 467 
exercised with chewable tablets in young children below 2 years due to the risk of choking 468 
(Michele et al., 2002). 469 
 470 
The risk of mis-dosing is highest where a patient or caregiver is required to identify and 471 
measure a specific volume of product using an administration device, or count a specific 472 
number of unit dosage forms.  Unless provided in unit dose packs, oral liquids require 473 
measurement of the prescribed dose for administration and various studies have 474 
investigated the accuracy and ease of measurement of oral liquids by caregivers with 475 
different devices.  Overall, dosing cups appear to have the highest error rates, although 476 
there are some conflicting results regarding the accuracy of measurement with oral syringes 477 
and measuring spoons (Beckett et al., 2012; Ryu and Lee, 2012; Tanner et al., 2014).  In 478 
Europe, oral syringes are commonly supplied by healthcare professionals to paediatric 479 
patients and caregivers for the administration of oral liquids, despite being the most 480 
frequently cited problematic measuring device; key problems reported include the 481 
identification of the correct dose and having difficulty in measuring the dose (Walsh et al., 482 
2015).  Older patients may face additional difficulties in the correct use of oral administration 483 
devices due to a decrease in hand function (e.g. grip strength and hand dexterity) (Carmeli 484 
et al., 2003) and visual impairment due to a deterioration of the function of the eye tissues 485 
with age and/or ocular pathology (e.g. presbyopia, cataracts, macular degeneration) (Loh 486 
and Ogle, 2004).  Clear and appropriate units of measure (e.g. mL) and simple instructions 487 
for use are important for reducing potential dosing errors (Yin et al., 2014; Yin et al., 2011).   488 
 489 
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Homogeneity of oral liquids is vital to ensure dose uniformity.  There is therefore a greater 490 
risk of mis-dosing with suspensions and emulsions compared to oral solutions, where the 491 
product may not be adequately shaken by the caregiver before dose administration.  Hence 492 
the ease with which the suspension or emulsion can be easily re-dispersed and the speed of 493 
sedimentation or phase separation (permitted standing time) need to be considered.  494 
 495 
Although no measurement of volume is required for the administration of effervescent and 496 
dispersible products, there are a number considerations  associated with administering these 497 
dosage forms.  The product must be allowed to fully effervesce/ disperse prior to 498 
administration and the full volume of liquid must be swallowed, including any residue; it may 499 
be necessary to rinse the container to ensure any residue is ingested.  Young children and 500 
adults on fluid restricted diets may struggle to ingest large volumes of liquid and so the 501 
volume required for dispersal should be kept to a minimum and indicated to the patient.  502 
 503 
Similar risks of mis-dosing to those described above for oral liquids are applicable to 504 
multiparticulates, unless they are presented in unit dose formats such as sachets.  505 
Graduated dosing spoons have been developed for the measurement of multi particulate 506 
products (Furin et al., 2013), however, little information appears to be available in the 507 
literature on the dosing accuracy and ease of use of such administration devices.  508 
Multiparticulates, including powders may be administered directly in the mouth or mixed with 509 
a food or beverage to facilitate swallowing (CHMP, 2006; van Riet-Nales et al., 2016b).  If 510 
mixed with food or beverage, the smallest quantity should be used to minimise the risk of 511 
incomplete consumption of the whole dose.  In addition, using this approach for product 512 
administration has the risk of potential instability and incompatibility of the formulation with 513 
the food/beverage, as well as a potential impact on the biopharmaceutical characteristics of 514 
the product, all of which can lead to inadvertent mis-dosing (EMA, 2013).  Powders for oral 515 
suspension are constituted with a specified volume of water or other vehicle prior to 516 
administration, and a high incidence of errors has been reported when this is conducted by 517 
the caregiver.  For example, addition of an incorrect volume of water or failure to adequately 518 
shake the bottle leading to incorrect concentration of product has been noted (Berthe-Aucejo 519 
et al., 2016).   520 
 521 
All other solid oral dosage forms discussed in this review are considered to have a low risk 522 
of mis-dosing, unless manipulated (e.g. cut or crushed) or requiring counting (e.g. multiple 523 
mini tablets).  Tablets may be manipulated to achieve the required dose or in response to 524 
patient preference.  However, such interventions can cause unknown effects on the stability 525 
and bioavailability of a product, together with a risk of inaccurate dosing (Richey et al., 526 
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2013).  Indeed, investigations into the cutting (splitting) of tablets have shown a wide 527 
variability in weight and content uniformity results, with drug content variability being 528 
attributed to weight variation in tablet halves, especially with unscored tablets (Habib et al., 529 
2014; Hill et al., 2009).  Where several mini tablets are required per dose, the use of a 530 
dispensing or counting device may be needed to facilitate accurate dosing (Aleksovski, et 531 
al., 2015).  Older patients whose manual dexterity is compromised may find the handling of 532 
mini tablets challenging due to their small size, which could lead to mis-dosing.   533 
 534 
Overall, when considering potential risks associated with excipient safety and administration 535 
errors, solid oral unit dosage forms offer a more favourable safety profile compared to oral 536 
liquids, although they provide less flexibility of dosing. 537 
5. Access  538 
Along with key considerations associated with patient acceptability and safety, enabling 539 
access to the medicine is fundamental, for patients of all ages.  There are many factors that 540 
impact accessibility of the medicine including the product stability, the complexity associated 541 
with its manufacture and the ability to supply the product from the manufacturing site to the 542 
patient.  Each of these factors may impact cost and affordability of the drug product and 543 
must be factored into the drug product design to ensure global availability.  A comparison of 544 
anticipated relative cost, stability risk, manufacturing complexity and supply chain challenges 545 
of various oral dosage forms compared to conventional tablets is provided in Table 4. 546 
 547 
Table 4 Relative cost, stability risk, manufacturing complexity and supply chain 548 
challenges of various oral dosage forms compared to conventional tablets 549 
Feature/ Dosage form Stability (shelf 
life & in use) 
Manufacturing 
& Development 
Supply Chain Cost 
Conventional tablets* 0 0 0 0 
Solution/Syrup/Drops ++ 0 ++ + 
Suspension/Emulsion ++ + ++ + 
Effervescent/ Dispersible 
tablet 
+ + + + 
Multi-particulates/Granules/ 
Beads/ Sprinkles/Powders 
+ +/++1 0 +/++1 
Mini tablets 0 + 0 0 
Hard gelatin capsules + 0 + 0 
Soft gelatin capsules 
(“Softgels”) 
+ ++ + + 
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Compressed oro-dispersible 
tablet 
0 + 0 0 
Lyophilisate/ melt + ++ + ++ 
Chewable dosage forms + + + + 
Oral films + ++ + ++ 
 550 
Key: 551 
Conventional tablets = 0 (reference value) * 552 
0 = equivalent risk/complexity compared to conventional tablets 553 
+ or ++ = greater risk, complexity or cost compared to conventional tablets 554 
1 Depends on technology used 555 
 556 
Traditionally, liquid oral dosage forms are selected as the dosage form of choice for dosing 557 
medicines to children due to their flexibility of dosing and ease of swallowing.  Indeed, they 558 
are considered to be suitable for the whole patient population as well as geriatric patients, 559 
notwithstanding the risks highlighted in section 3 (providing the excipients are considered to 560 
have acceptable safety) (Table 2).  However, the stability of such products can be very 561 
challenging and hence their shelf life may be limited.  For example, physical, chemical and 562 
microbial instability can arise due to the API being solubilised or suspended in a vehicle that 563 
may cause oxidation, or an aqueous vehicle that may be prone to microbial spoilage.  These 564 
formulations may consequently require storage in a refrigerator to avoid microbial spoilage 565 
and/or minimise chemical instability which may have implications for transportation and their 566 
suitability in resource poor territories.  The requirement for specialised storage conditions 567 
together with a potentially relatively short shelf life may negatively impact the supply chain, 568 
since cold chain supply can be very costly and may be very difficult to control between 569 
manufacturing and receiving sites, and cold storage can be inconvenient for the end user.  570 
An additional consideration for the product supply chain is the size and dimensions of the 571 
primary and secondary packaging.  Multi use packs can offer convenience to the end user 572 
but may be costly to transport due to their bulkiness, whilst single use packs e.g. sachets, 573 
are individually smaller but may increase the overall packaging requirements and 574 
consequently drive up the total cost of each unit dose.  575 
 576 
From a manufacturability perspective, oral liquid formulations such as solutions and syrups 577 
are relatively straightforward to prepare.  Solutions for example, may be manufactured using 578 
a simple process using non-complex equipment.  A pH adjustment step may be required at 579 
the end of manufacture.  The solution is filled into multi use or single use bottles using 580 
suitably precise filling equipment.  Suspensions and emulsions, however, may require the 581 
use of an homogeniser to prepare a physically stable suspension or emulsion to avoid the 582 
risk of sedimentation or flocculation of the suspension and separation of the emulsion.  583 
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Suspensions and emulsions are therefore more complex to develop and manufacture than 584 
solutions. 585 
 586 
Due to the stability challenges associated with oral liquid products, there is an increasing 587 
focus on the development of age appropriate solid oral products (WHO, 2008).  Tablet 588 
dosage forms (including effervescent, dispersible and chewable tablets), are typically more 589 
stable than liquid formulations.  There is less microbial spoilage risk due to low moisture 590 
content levels, and being in the solid form, chemical and physical stability risk is also 591 
significantly reduced.  However instability as a result of API-excipient interactions can still 592 
occur and may be exacerbated by the long term storage conditions that the product may be 593 
subjected to post manufacture, for example temperature and humidity.  ODTs and to some 594 
extent dispersible/effervescent tablets may be prone to moisture absorption on storage due 595 
to the design of the matrix and the excipients selected.  Such products may require 596 
protection from moisture (via moisture protective packaging) to enable adequate shelf life.  597 
 598 
Typically tablet manufacture does not require the use of highly sophisticated pieces of 599 
equipment or particularly advanced technologies.  Tablets may be prepared using direct 600 
compression or by wet or dry granulation followed by compression and film coating as 601 
appropriate.  API properties such as bulk density, particle size and particle shape can 602 
influence the manufacturing process (Leane et al., 2015).  The complexity and cost of the 603 
manufacturing process depends on the number of unit operations required.  An added 604 
complication for the manufacture of mini tablets is the requirement to ensure content 605 
uniformity of each individual unit tablet if the mini tablets are intended to be taken as 606 
individual dose units, which requires strict control of particle size and powder flowability.  607 
This is a significant challenge given the low compression weight of mini tablets (Aleksovski 608 
et al., 2015).  Due to their small size and generally superior stability, the transportation and 609 
storage of tablets tends to be less costly compared to liquids.  Conventional tablets often do 610 
not require specialised packaging and a number of unit doses may be packed into a small 611 
pack (such as a blister or bottle), which minimises volume and mass and hence reduces 612 
shipping cost.  Alternatively conventional tablets may be supplied in bulk format for hospital 613 
settings without impact on the stability or shipping costs. 614 
 615 
Chewable tablets may be manufactured via conventional tabletting processes, or if 616 
gelatin/confectionary-based, by more complex methods which may be patented and involve 617 
for example extrusion or moulding.  Similarly, the complexity and hence cost of 618 
manufacturing ODTs depends upon the technology used.  ODTs may be manufactured by 619 
direct compression of polysaccharide based excipients which is relatively inexpensive, or 620 
FINALv1 with tables 2017_FL_JW  
may utilise relatively expensive, specialised and patented manufacturing processes such as 621 
freeze drying (lyophilisation) (Al-khattawi and Mohammed, 2013; Badgujar and Mundada, 622 
2011; Baltzley et al., 2014).  As discussed above, ODTs and in particular freeze-dried 623 
formulations are likely to require moisture protective packaging which could increase 624 
packaging cost. 625 
 626 
Fast disintegrating oral films are a similar alternative to ODTs in that they are easy to 627 
swallow and can be taken without water, although the dose is restricted to <75mg to 628 
minimise the size of the film.  The formulations are reasonably simple with the API typically 629 
being dissolved in a polymer solution.  However, the manufacturing process is very 630 
specialised and the films are prone to moisture absorption and hence often packed in foil 631 
pouches for protection, leading to a higher cost compared to more conventional solid oral 632 
dosage forms (Borges et al., 2015; Hoffmann et al., 2011). 633 
 634 
Multiparticulates are considered to offer advantages of both liquid and solid oral products in 635 
that they are easy to swallow and enable dose flexibility whilst having  stability properties 636 
generally comparable to conventional tablets and low risk of microbiological spoilage.  As 637 
with ODTs, complexity of manufacture depends on the technology used, and is also related 638 
to number of unit processes required.  For example, the simplest multiparticulate product 639 
may comprise a mixture of powders.  In contrast, multiparticulates such as granules and 640 
spheroids (beads) may require more advanced equipment and know-how (for example melt 641 
granulators, spray dryers, extruders and/or spheronisers) (Gandhi B, 2013).  Non-powder 642 
multiparticulates are often coated with a polymer which can act to modify API release or to 643 
provide taste masking.  Once coated, the multiparticulates require curing to ensure that the 644 
coat is completely annealed and then they are typically filled into capsules or single unit 645 
packs such as sachets.  Such technology may render the process too complex and 646 
expensive for low cost manufacturing facilities although supply chain considerations are 647 
likely to be similar to those for tablets. 648 
 649 
As stated above, hard capsules are usually filled with multiparticulates (especially powders) 650 
although they may also be filled with semi solid materials such as lipidic based formulations.  651 
The stability of both the capsule contents and shell must be considered.  Hard capsules are 652 
most commonly manufactured from gelatin or hypromellose and consequently their integrity 653 
may be impacted by humidity.  The inclusion of a desiccant in the primary packaging to 654 
improve overall product stability may result in gelatin capsules becoming brittle due to 655 
dehydration.  Furthermore the iteration between the fill of the capsule and the capsule shell 656 
must also be considered, since gelatin can cross link with some materials resulting in a delay 657 
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in capsule disintegration (Gullapalli and Mazzitelli, 2017).  Hard capsule filling is a relatively 658 
simple manufacturing process using either volume or gravimetric filling systems.  Typically 659 
power blends are filled but API alone may be filled if the material has appropriate flow 660 
characteristics.  Once prepared, the capsules may be packaged into bottles or blister packs 661 
and consequently this is a relatively cheap process that is routinely used for providing drug 662 
products to resource poor regions. 663 
 664 
Soft gel capsules are generally used for liquid fill, for example lipid-based formulations for 665 
poorly soluble APIs and high potency APIs where content uniformity can be problematic.  666 
Stability can be particularly challenging for these dosage forms due to potential 667 
incompatibility between the liquid/semi-solid fill formulation and the gel capsule, as well as 668 
possible temperature and humidity effects on the capsule shell.  The development and 669 
manufacture of soft gel formulations can be complex and requires the use of specialised 670 
equipment (Gullapalli and Mazzitelli, 2017).  Hence the risks associated with stability and the 671 
complexity of manufacture and development significantly increase the cost of soft gel 672 
capsules. 673 
 674 
From a manufacturability perspective, typically conventional tablet dosage forms offer the 675 
least stability risk, the simplest manufacturing processes, enable a simple and cost effective 676 
supply chain and hence are a low cost dosage form option.  However, these considerations, 677 
together with those outlined for other dosage types must be evaluated in combination with 678 
patient acceptability and patient safety.  Dispersible tablets offer an advantage over 679 
conventional tablets by overcoming swallowing difficulties faced by some paediatric and 680 
geriatric patients.  681 
 682 
6. Other dosage forms and Innovations  683 
This review has focussed on commonly used and well-known oral dosage forms, however 684 
the authors have investigated a number of other novel formats, but little information, if any, 685 
appears to be available on their patient acceptability.  Although historically sugar-based 686 
medicated oral lozenges (lollipops) have been indicated for the relief of sore throats due in 687 
part to their demulcent properties, the utilisation of this dosage form for the treatment of local 688 
infections and systemic conditions has gained interest in recent years (Rao et al., 2012).  For 689 
example, sugar-based lollipops (lozenges) have been developed for the local treatment of 690 
oral thrush in children and also as a means for administering the anthelmintic Levamisole to 691 
paediatric patients (Kamath et al., 2012).  In addition, Actiq® (Fentanyl citrate) transmucosal 692 
lozenges are available for the management of breakthrough pain in cancer patients from 16 693 
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years.  Lozenges/ lollipops offer the advantage of being suitable for patients who have 694 
difficulty swallowing tablets since they are intended to be slowly sucked.  However, there is a 695 
risk of choking together with the potential to cause dental caries due to the sucrose within 696 
the formulation. 697 
 698 
Chewing gum has also been available for many years, and is now being considered for use 699 
as a modified release drug delivery system.  It is intended to be chewed for a certain period 700 
of time to deliver the drug, after which the remaining mass should be discarded.  As with 701 
lozenges/ lollipops, medicated chewing gum may be taken without water and can provide 702 
both systemic and local drug delivery.  In addition, it is perceived to be accepted by children 703 
and teenagers, although there is a potential choking risk.  Different chewing styles may lead 704 
to differences in drug release rates and the chewing action may not be culturally and/or 705 
physically acceptable to some patients, especially the elderly (Aslani and Rostami, 2015; 706 
Khatun and Sutradhar, 2012). 707 
 708 
The use of hydrophilic oral gels (jelly) for the elderly is an area of interest, especially in 709 
Japan where a number of oral jelly products are currently available.  The products are 710 
provided in unit dose packs and have the advantage of being easy to swallow, without the 711 
need for water (Imai, 2013).  Hence oral gels are likely to be appropriate for all patients who 712 
have difficulty swallowing solids, including young children (Gohel et al., 2009).  Oral gels 713 
have also been investigated as a potential vehicle to facilitate the administration of mini 714 
tablets and pellets (Kluk et al., 2015).  In Japan, an agar-based jelly (Swallowing Aid Jelly 715 
(“Magic Jelly”)) has been developed to assist medicine administration in both elderly and 716 
paediatric patients (Ryukakusan Co. Ltd, https://www.ryukakusan.co.jp/productjelly/en).  In 717 
European Nordic countries and Germany, a special coating (MEDCOAT®) is available that 718 
can be applied to tablets and capsules by patients to assist swallowing.  The coating 719 
becomes very slippery in contact with water or saliva and also contains saliva stimulating 720 
ingredients that further improve swallowing (http://www.medcoat.com/). 721 
 722 
The development of printed medicines has gained interest in recent years, and may offer the 723 
potential for personalised medicines whereby the dose of API and product properties are 724 
tailored to the patient.  For example, the feasibility of printing API onto porous substrates and 725 
oro-dispersible films has been investigated, which may provide a platform technology 726 
suitable for the accurate administration of low dose and poorly soluble APIs (Janssen et al., 727 
2013; Sandler et al., 2011).  3D printing may also be used for the preparation of medicinal 728 
products, for example the first 3D printed medicine (Spritam®, Levetitacetam) was approved 729 
by the FDA in 2015 (Prasad and Smyth, 2016).  This product utilises ZipDose® technology 730 
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whereby powder blend is deposited as a single layer, and an aqueous binding fluid is 731 
applied. Interactions between the powder and liquid bind these materials together.  The 732 
process is repeated several times to produce solid, yet highly porous formulations.  The 733 
development of 3D-printed tablets containing multiple drugs has been investigated 734 
(“polypill”), which may offer simplified dosing regimens and hence improved adherence for 735 
those patients taking many separate tablets (Khaled, 2015a; 2015b).  It is clear that printed 736 
medicines may offer many advantages to the elderly and paediatric patients, although further 737 
research is required. 738 
 739 
Inventions and development of novel platforms should be encouraged although the three 740 
aspects i) acceptability, ii) safety and iii) patient access discussed in this review must be 741 
considered for them to be adopted by industry and accepted by patients.  It should also be 742 
acknowledged that whilst it is aspirational that there is a single dosage from that can meet 743 
these defined criteria across the paediatric or geriatric populations, it is very likely that more 744 
than one dosage form will be required. 745 
7. Conclusions  746 
This review provides a comprehensive comparison of various oral dosage forms relating to 747 
evidence-based patient acceptability, safety and access, to assist pharmaceutical product 748 
formulators to select and develop the most suitable product for their intended patient 749 
population.  The ideal age appropriate drug product design should consider i) acceptability ii) 750 
safety and iii) access. 751 
 752 
However, the review has identified a number of knowledge gaps in terms of the impact of 753 
various dosage form attributes on the acceptability of the product in both paediatric and 754 
geriatric patients.  Although the evaluation of patient acceptability of various dosage forms is 755 
gaining interest, there is still a huge lack of information, knowledge, and in some cases 756 
conflicting evidence in this area.  It is therefore suggested that pharmaceutical companies 757 
and academia should be encouraged to conduct research into and publish any data they 758 
generate regarding dosage form acceptability.  Furthermore, since companies are required 759 
to evaluate patient acceptability during paediatric clinical studies (EMA, 2013), it is proposed 760 
that the European Medicines Evaluation Agency (EMA) publish anonymised information on 761 
for example swallowability of different sized solid oral dosage forms according to patient age.  762 
Regulatory guidance should be updated to reflect current evidence-based knowledge.  It is 763 
recognised that patient acceptability may be influenced by many factors, but the availability 764 
of such information in the public domain would facilitate pharmaceutical product design.  765 
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Despite these challenges, a valuable overview of literature evidence on patient acceptability 766 
has been provided. 767 
 768 
Key safety considerations have been highlighted and summarised.  The safety of a number 769 
of excipients has been reviewed as part of the on-going process for updating the EU 770 
guideline on excipients in the label and package leaflet of medicinal products for human use 771 
(EMA, 2012).  This has provided a valuable source of information although there still 772 
appears to be a dearth of information available on the safety and tolerability of many 773 
commonly used excipients in paediatrics and the elderly, especially their long term use.  In 774 
the case of neonates, infants and young children, this has often led to the need to utilise 775 
juvenile animal data (when available), to support their use.  Additional data are required to 776 
support the robust assessment of excipient benefits versus their potential risks within a 777 
formulation.  The publication of emerging data both from researchers and regulatory 778 
authorities is therefore encouraged to help fill the gaps.  Similarly, it is suggested that 779 
companies and excipient suppliers are encouraged to make public their safety data on 780 
excipients, for example by sharing it via the EuPFI Safety and Toxicity of Excipients in 781 
Paediatrics database (Salunke et al., 2013).  This would reduce the potential for duplication 782 
of excipient safety studies. 783 
 784 
The evaluation of the accessibility (stability, ease/cost of development, manufacture and 785 
supply) of the oral dosage forms has highlighted that those with the most favourable access, 786 
for example conventional tablets, may not necessarily be the most acceptable for all 787 
patients.  In a similar manner, oral dosage forms reported to have high patient acceptability, 788 
for example oral liquids, may be less favourable from a safety of excipients and supply 789 
perspective.  This clearly illustrates that a single “ideal” dosage form does not exist.  It 790 
should be recognised that patient acceptability, safety and access must be balanced against 791 
each other and in some situations a compromise may need to be reached when selecting an 792 
age-appropriate formulation. 793 
 794 
This research did not receive any specific grant from funding agencies in the public, 795 
commercial or not-for-profit sectors.   796 
  797 
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